Drug Trial Radar · NCT06041646
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Oct 2, 2023
Primary completion
Apr 29, 2024
Study completion Apr 29, 2024
Sponsor
- Lead sponsor
- BioXcel Therapeutics IncIndustry
- Sponsor type
- Industry
- Collaborators
- Lotus Clinical Research, LLC
- First posted
- Sep 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
Conditions
- Bipolar Disorder
- Schizophrenia
- Agitation,Psychomotor
- Schizo Affective Disorder
- Schizophreniform Disorders
Interventions
Sublingual film containing IgalmiDrug
Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total ScoreTime frame: Baseline and 2 hours post-dose for all doses administered over 7 days.
- Clinical Global Impression - Improvement (CGI-I)Time frame: 2 hours post-dose for all doses administered over 7 days.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
BioXcel Clinical Research Site
Little Rock, Arkansas
BioXcel Clinical Research Site
Rogers, Arkansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.